GLP1R and metabolic dysfunction-associated steatotic liver disease: GLP-1 receptor agonists, such as semaglutide, reduce hepatic fat deposition and improve insulin resistance, with studies demonstrating benefits for liver fat content and inflammatory markers in MASLD patients, though further research is needed to confirm long-term efficacy and antifibrotic effects (61).